Short answer
Ozempic is the brand name of semaglutide at the doses used for type 2 diabetes, up to 2 mg a week. It is not approved for weight loss without diabetes; for that, semaglutide 2.4 mg is available as Wegovy. Because of shortages, authorities ask that Ozempic be used for diabetes only. OpenClinic24 follows the approved indications.
Key facts
Ozempic contains semaglutide and has been approved in the EU since 2018 for inadequately controlled type 2 diabetes, at doses up to 2 mg a week.
Cardiovascular trial in type 2 diabetes (NEJM 2016, 3,297 participants): major cardiovascular events in 6.6 per cent with semaglutide versus 8.9 per cent with placebo.
Any use outside type 2 diabetes, including weight loss, is off-label and, according to a manufacturer letter published by the BfArM, endangers supply for people with diabetes.
Semaglutide 2.4 mg (Wegovy) is approved for weight management: minus 14.9 per cent body weight after 68 weeks in STEP 1 (NEJM 2021).
In 2023 the EMA warned of falsified Ozempic pens at wholesalers; only medicines from a pharmacy on prescription are safe.
What Ozempic is
Ozempic is the brand name of a prefilled pen containing semaglutide. Semaglutide is a GLP-1 receptor agonist: it mimics the gut hormone GLP-1, which is released after eating. GLP-1 increases insulin release when blood sugar is high, lowers glucagon, slows stomach emptying and strengthens the feeling of fullness in the brain. Drucker describes these mechanisms in detail in a review in Cell Metabolism.
In the EU, Ozempic has been approved since 2018 for adults with inadequately controlled type 2 diabetes, alongside diet and exercise, alone or with other diabetes medicines. The product information in the European Medicines Agency’s assessment report sets out dosing, contraindications and side effects. It is injected under the skin once a week.
The name has become known far beyond diabetes care because many people lost a lot of weight on it. This has created a misunderstanding that this article aims to clear up: Ozempic is a diabetes medicine. Separate medicines are approved for weight management.
Effect in type 2 diabetes
Semaglutide markedly lowers long-term blood sugar (HbA1c) and supports weight loss, which is an important goal in type 2 diabetes. It also benefits the heart: in a trial of 3,297 people with type 2 diabetes and high cardiovascular risk, cardiovascular death, heart attack or stroke occurred in 6.6 per cent on semaglutide and 8.9 per cent on placebo (Marso and colleagues, NEJM 2016), about a quarter lower risk.
According to the product information, dosing starts at 0.25 mg a week for four weeks, a dose for getting used to the medicine that hardly lowers blood sugar yet. It then goes up to 0.5 mg; if that is not enough, to 1 mg after at least four weeks and to 2 mg if needed. Anyone also taking insulin or sulfonylureas often needs these adjusted to avoid low blood sugar.
Ozempic for weight loss: why it is not the right route
Ozempic is not approved for weight loss without diabetes. Doctors may prescribe outside an approval in individual cases, but only with particular justification, information and liability. With Ozempic there is a second reason: supply. A manufacturer letter of July 2024, published by the BfArM, states that any use outside type 2 diabetes, including weight management, is off-label and endangers availability for people with diabetes.
The BfArM advisory board on supply shortages had already noted that consumption has risen steadily since early 2022, partly due to use in obesity treatment, with the low strengths repeatedly in short supply. For people with type 2 diabetes who depend on the medicine, this is a real problem.
For weight management there is a better option: semaglutide at a higher dose is approved for exactly this purpose as Wegovy. In the STEP 1 approval trial, adults with obesity without diabetes lost 14.9 per cent of their weight over 68 weeks, compared with 2.4 per cent on placebo. Read more in Wegovy (semaglutide 2.4 mg). Another approved substance is tirzepatide, see Mounjaro (tirzepatide).
Weight loss with medical support
A doctor assesses by video whether a medical treatment is an option for you and supports you with a plan and follow-up appointments. Treatment follows the approved indications; the decision is made case by case.
Check eligibility in 5 questionsOzempic and Wegovy compared
| Ozempic | Wegovy | |
|---|---|---|
| Active substance | semaglutide | semaglutide |
| Approval | type 2 diabetes | weight management in obesity or overweight with a related condition |
| Maximum weekly dose | 2 mg | 2.4 mg |
| Escalation | 0.25 mg, 0.5 mg, then 1 mg and 2 mg if needed | 0.25 mg to 2.4 mg over 16 weeks |
| German statutory insurance | possible for type 2 diabetes | no, § 34 SGB V |
The pens are not interchangeable, and switching between products belongs in medical hands. People with type 2 diabetes and excess weight are treated according to the diabetes approval; whether a weight management product is also sensible is decided individually.
Shortages and falsified pens
High demand attracts counterfeits. In October 2023 the EMA warned of falsified Ozempic pens found at wholesalers in the EU and UK, labelled in German and originating from wholesalers in Austria and Germany. They were detected because their serial numbers showed as inactive when scanned. According to the agency they were not dispensed to patients through legal pharmacies. The BfArM also provides information on counterfeits of this medicine.
The key rule is simple: semaglutide only on prescription and only from a pharmacy. Offers on social media, classified ads, in gyms or in foreign online shops without a prescription are risky, because counterfeit pens can contain the wrong substance, the wrong dose or contaminants.
Side effects
The most common side effects are nausea, diarrhoea, vomiting and constipation, especially at the start and after dose increases. Less common are gallstones, pancreatitis and worsening of existing diabetic eye disease when blood sugar falls very quickly. In 2025 the EMA classified NAION, a circulation disorder of the optic nerve with sudden loss of vision, as a very rare side effect of all semaglutide medicines, affecting up to 1 in 10,000 people. In April 2024 the EMA’s safety committee concluded that the available data do not support a causal link with suicidal thoughts. More in Side effects of weight loss injections.
Costs and insurance
For type 2 diabetes, Ozempic can be prescribed at the expense of statutory health insurance if the criteria are met. For weight loss, statutory insurance pays nothing: § 34 (1) SGB V excludes medicines for weight reduction and appetite control. Private insurers decide according to the policy; off-label use is generally not reimbursed. The overall picture is in Weight loss injections.
When you need urgent medical help
Call 112 for severe upper abdominal pain radiating to the back, loss of consciousness from low blood sugar, shortness of breath or swelling after the injection and sudden loss of vision. For ongoing vomiting or signs of dehydration outside surgery hours, call the German on-call medical service on 116 117. Diabetes control, dose questions and side effects can be discussed well by video; acute symptoms, eye examinations and blood tests need an in-person visit.
When you need help immediately
- Severe, persistent upper abdominal pain radiating to the back: possible pancreatitis
- Shaking, sweating, sudden hunger, confusion while also on insulin or sulfonylureas: possible low blood sugar
- Sudden loss of vision or rapidly worsening sight in one eye
- Ongoing vomiting with signs of dehydration: very little urine, dizziness, racing heart
- Swelling of the face or tongue, shortness of breath after the injection
With these warning signs call the emergency number 112. Outside office hours the medical on-call service is available on 116 117. In these situations a video consultation does not replace an in-person examination.
Sources
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016. DOI: 10.1056/NEJMoa1607141 Study
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183 Study
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 2018. DOI: 10.1016/j.cmet.2018.03.001 Review
- Ozempic (semaglutide): European public assessment report (EPAR) and product information. European Medicines Agency (EMA), 2025. Authority
- Information letter on supply shortages of Ozempic and Victoza (July 2024). Federal Institute for Drugs and Medical Devices (BfArM), Novo Nordisk Pharma GmbH, 2024. Authority
- Recommendation of the advisory board on supply shortages: semaglutide and dulaglutide. Federal Institute for Drugs and Medical Devices (BfArM), 2023. Authority
- EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens. European Medicines Agency (EMA), 2023. Authority
- PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. European Medicines Agency (EMA), 2025. Authority
- § 34 German Social Code, Book V: excluded medicines. Federal Ministry of Justice, gesetze-im-internet.de, 2026. Law
All sources were retrieved during the medical review. Studies are linked by DOI; guidelines and laws in their current version.
Frequently Asked Questions
What is Ozempic?
Ozempic is the brand name of a prefilled pen containing semaglutide. Semaglutide mimics the gut hormone GLP-1: it increases insulin release when blood sugar is high, slows stomach emptying and reduces appetite. In the EU, Ozempic is approved for adults with inadequately controlled type 2 diabetes, alongside diet and exercise, and is injected once a week.
Can I get Ozempic for weight loss?
Ozempic is not approved for weight loss without diabetes. Prescribing outside the approval is legally possible, but authorities explicitly discourage it because of ongoing shortages that threaten supply for people with type 2 diabetes. Separate medicines are approved for weight management; whether one of them suits you is assessed by a doctor.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide. Ozempic is approved for type 2 diabetes and dosed up to 2 mg a week. Wegovy is approved for weight management and dosed up to 2.4 mg a week, with its own escalation scheme and pens. They are not interchangeable; which one is appropriate depends on the diagnosis and the approval.
How is Ozempic dosed?
According to the product information, treatment starts with 0.25 mg once a week for four weeks and is then increased to 0.5 mg. If blood sugar control is not sufficient, the dose can be raised to 1 mg after at least four weeks and later to 2 mg. It is injected on a fixed day of the week, regardless of meals.
Why is Ozempic in short supply?
Since 2022 demand has risen sharply, partly due to off-label use for weight loss. The German Federal Institute for Drugs and Medical Devices (BfArM) has repeatedly published letters about supply shortages, especially for the low strengths. People with type 2 diabetes already on treatment should be supplied first; during shortages, treatment is switched in agreement with the doctor.
How can I recognise fake Ozempic pens?
In October 2023 the EMA warned of falsified pens found at wholesalers in the EU and UK, labelled in German. According to the agency, they were not dispensed through legal pharmacies. Never buy semaglutide from classified ads, social media or foreign shops without a prescription, and return any suspicious pen to the pharmacy.
Does health insurance pay for Ozempic?
For type 2 diabetes, Ozempic can be prescribed at the expense of German statutory health insurance if the criteria are met. For weight loss, statutory insurance does not pay, because § 34 SGB V excludes medicines for weight reduction. Private insurers decide according to the policy; reimbursement of off-label use is generally not to be expected.
What are the side effects of Ozempic?
The most common are nausea, diarrhoea, vomiting and constipation, especially after dose increases. Less common are gallstones and pancreatitis. In 2025 the EMA classified a circulation disorder of the optic nerve, called NAION, as a very rare side effect, affecting up to 1 in 10,000 people treated. Sudden loss of vision needs urgent medical assessment.
About the author
Note: This article provides general information and does not replace individual medical advice, diagnosis or treatment. If you have symptoms, contact a doctor; in an emergency call 112.
